How to Value a Rheumatology Practice in 2026

Rheumatology practices have quietly become some of the most attractive acquisition targets in physician services. The combination of biologic infusion revenue, chronic disease patient panels, and a severe provider shortage has created a seller's market that most rheumatologists don't fully appreciate. I've watched multiples in this specialty climb steadily over the past five years, and the dynamics driving that trend aren't slowing down.

If you own a rheumatology practice — especially one with an in-office infusion suite — you're sitting on a more valuable asset than you probably realize. Here's how the market actually prices these practices.

Why Rheumatology Commands Premium Multiples

Rheumatology practices trade at 5-9x EBITDA, with infusion-heavy practices at the upper end and E&M-only practices closer to the bottom. That range puts rheumatology above most primary care specialties and in line with gastroenterology and dermatology — the other physician services niches that private equity has aggressively targeted.

Three structural factors drive these premiums, and understanding them is critical to positioning your practice for maximum value.

The biologic infusion revenue model.This is the single biggest value driver in rheumatology. When you administer Remicade, Orencia, Rituxan, or any of the other IV biologics in your office, you're operating a buy-and-bill model where drug acquisition cost is $3,000-$8,000 per infusion and reimbursement is 20-30% above your acquisition cost. An infusion suite running 15-20 chairs can generate $2-4M in annual drug revenue alone, with margins of 18-25% on the drug spread. Buyers look at infusion revenue the way SaaS investors look at recurring revenue— it's predictable, sticky, and high-margin.

Chronic disease panels are inherently recurring.Rheumatoid arthritis, lupus, psoriatic arthritis, vasculitis — these conditions require lifelong management. A patient diagnosed with RA at 45 will see their rheumatologist regularly for the next 30+ years. Your active patient panel represents decades of future revenue that doesn't require marketing spend to maintain. Buyers model this as annuity-like cash flow.

The provider shortage is structural.There are roughly 5,500 practicing rheumatologists in the U.S. serving a population that needs approximately 7,000-8,000. Rheumatology fellowship programs produce only 250-300 new rheumatologists per year while retirements outpace new graduates. This supply-demand imbalance means your patients can't easily switch to a competitor — there often isn't one within 50 miles. For buyers, that means lower patient attrition risk post-acquisition.

The Buy-and-Bill Economics That Drive Value

I need to spend time on infusion economics because it's where most of the valuation variance lives. Two rheumatology practices with identical patient volumes can have wildly different valuations based on their infusion operations.

The buy-and-bill model works like this: you purchase biologic drugs at wholesale (typically through a GPO or specialty distributor), administer them in your office, and bill the payer at ASP+6% (Medicare) or a negotiated rate (commercial). Your margin is the spread between acquisition cost and reimbursement, plus the administration fee (J-codes).

Payer mix matters enormously. Commercial insurance reimburses biologics at significantly higher rates than Medicare. A practice with 40% commercial payer mix on infusions might earn 25% margins on drug spend, while a Medicare-heavy practice earns 8-12%. This single variable can swing practice EBITDA by hundreds of thousands of dollars — and multiples by 2-3 turns.

Biosimilar strategy affects margins.The shift toward biosimilars (Inflectra for Remicade, Hadlima for Humira in IV formulation) creates both opportunity and risk. Practices that have proactively transitioned appropriate patients to biosimilars often maintain or improve margins through better contract rates, while also demonstrating to buyers that they're operationally sophisticated and not dependent on single-drug economics.

340B eligibility is a multiplier. If your practice is affiliated with a 340B-eligible health system or FQHC, the drug acquisition discount dramatically improves margins. Practices with 340B access consistently trade at the top of the multiple range. But buyers also scrutinize 340B arrangements carefully — the regulatory landscape is shifting, and over-reliance on 340B pricing introduces policy risk.

What PE Buyers Are Looking For

Private equity interest in rheumatology has accelerated since 2022. Several platforms are actively building rheumatology management organizations, and they're paying premium multiples to acquire anchor practices. Here's what separates a 5x practice from a 9x practice in their eyes.

Scale of infusion operations. A practice running a 10+ chair infusion suite with dedicated nursing staff, inventory management systems, and robust prior authorization workflows is a platform. A practice that does occasional infusions in an exam room is an add-on. Platform practices command 7-9x; add-ons get 5-6x.

Provider depth. Solo rheumatologists are a risk. If you leave, the entire patient panel is at risk. Practices with 2-4 rheumatologists, plus APPs handling routine follow-ups, demonstrate that the business survives any single departure. This directly parallels the owner dependency problem across all professional services.

Geographic coverage.PE buyers building rheumatology platforms want density in a region. If you have satellite offices covering a 100-mile radius, you're more valuable than a single-location practice — even at the same EBITDA — because you've already solved the geographic expansion problem.

Clean referral relationships.Rheumatology depends on primary care referrals. Buyers will map your referral sources and assess concentration risk. If 40% of your new patients come from one health system that could bring rheumatology in-house, that's a discount.

What Kills Rheumatology Practice Value

No in-office infusion.A rheumatology practice that refers all infusions to hospital outpatient departments or home infusion companies is leaving its most valuable revenue stream on the table. Buyers see this as both a missed opportunity and a signal that the practice lacks operational ambition. If you don't have an infusion suite, building one 18-24 months before a sale can dramatically increase your exit value.

Over-reliance on a single biologic.If 70% of your infusion revenue comes from one drug, you're exposed to formulary changes, biosimilar substitution mandates, and manufacturer contracting shifts. Diversification across multiple biologics reduces risk in buyers' models.

Weak prior authorization infrastructure.Biologics require extensive prior authorization work. Practices with high denial rates, slow PA turnaround, or no dedicated PA staff signal operational problems that buyers will have to fix — and they'll price that fix into their offer.

Solo provider with no succession plan. A 62-year-old solo rheumatologist with 3,000 patients and no associate is simultaneously the most needed and the hardest to sell. The provider shortage works both ways — it drives up your practice value, but it also makes finding a replacement physician to ensure continuity extremely difficult.

Maximizing Your Rheumatology Practice Value

Build or expand your infusion suite.If you're referring infusions out, bring them in-house. If you have 6 chairs, consider expanding to 12. The capital investment ($200-400K for buildout and initial inventory) typically pays back within 12-18 months and can add $1M+ to your practice valuation.

Recruit a second rheumatologist. Even if it compresses your personal income in the short term, a two-provider practice is worth substantially more than a solo practice. The provider shortage means you may need to offer partnership or competitive compensation, but the valuation math justifies it.

Optimize your payer contracts.Renegotiate commercial rates on infusion drugs annually. The difference between a 20% and 25% margin on $3M in drug spend is $150K in annual EBITDA — at a 7x multiple, that's over $1M in enterprise value.

Document your patient panel rigorously. Buyers want to see active patient count by diagnosis, infusion patient count, average visits per patient per year, and new patient wait times (longer waits actually signal demand strength). Clean data accelerates due diligence and reduces buyer uncertainty.

The Bottom Line

Rheumatology is one of the most compelling physician specialties from a valuation perspective. The combination of high-margin infusion revenue, inherently recurring patient relationships, and a structural provider shortage creates conditions that favor sellers — particularly those who've invested in building out their infusion operations and recruiting additional providers. If you're a rheumatologist thinking about an exit in the next 3-5 years, the market conditions are as favorable as they've ever been. The question is whether your practice is structured to capture that value, or whether you're leaving it on the table by operating as a high-income solo practice instead of a scalable platform.